Navigation Links
Data on VIVUS' Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting
Date:6/2/2009

MOUNTAIN VIEW, Calif., June 2 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS), a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health, today announced that Qnexa data will be featured in two podium presentations during the 69th Scientific Sessions of the American Diabetes Association (ADA), being held from June 5-9, 2009 in New Orleans, Louisiana. Previous studies have shown significant weight loss with Qnexa treatment. Both podium presentations will highlight the benefit of weight loss and the corresponding positive impact on type 2 diabetes. Data from the phase 3 EQUATE trial (OB-301) shows that weight loss with Qnexa stops the progression of type 2 diabetes in obese, non-diabetic patients. The results of a year-long phase 2 diabetic study, DM-230, demonstrate that weight loss with Qnexa can significantly lower blood sugar in type 2 diabetics.

"Obesity and type 2 diabetes, which are inextricably linked, are growing at epidemic proportions worldwide and physicians need new, more effective treatment options for the millions of patients at risk," commented Leland Wilson, president and chief executive officer of VIVUS. "In clinical studies to date, Qnexa has demonstrated significant impact on patients' weight, glucose levels, HbA1c and other critical cardiovascular risk factors, in patients with and without diabetes. We are delighted that Qnexa data from our previously reported phase 3 obesity study and our previously reported year-long diabetes study have been selected for podium presentations at the ADA annual meeting."

Details for the two oral podium presentations of Qnexa data follow:

Date and Time: Saturday, June 6, 2009, 4:00-6:00 P.M.

Session: Novel Diabetes Treatments in Development in Humans'/>"/>

SOURCE VIVUS, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. VIVUS Reports First Quarter 2009 Financial Results and Highlights
2. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
3. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
4. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
5. Results of Colon Cancer Study Utilizing Pressure Cycling Technology (PCT) Presented at the American College of Gastroenterology Annual Scientific Meeting
6. Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics
7. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
8. Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference
9. Salugens Award-Winning Research on Using DNA Information to Customize Nutritional Supplementation for Weight Loss Presented at the Second Annual Bruce Ames International Symposium on Nutritional Genomics at the University of California, Davis
10. Reverse Cholesterol Transport by RVX-208 a Small Molecule for ApoA-I Production Increase Presented at American Heart Association Scientific Meeting
11. Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... BioTrends Research Group, one of the ... biopharmaceutical issues, finds that, unaided, one in five ... that in the past six months, they have ... anticipation of the next generation of HCV treatments—notably ... 6 percent reported that they had begun warehousing ...
(Date:5/23/2013)... -- Z Trim Holdings, Inc. (OTC Markets: ZTHO), a ... industries, announced that Chef Erin Ryan ... National Restaurant Association ("NRA") NRA Show, which was held ... Chefs Association.  Chef Ryan spoke on the subject of ... the Ugly," joining four other prestigious panelists including:  Kit ...
(Date:5/23/2013)... 23, 2013 The New Jersey chapter ... Black Data Processing Associates (BDPA), is hosting its 10th ... 2013. This all-day event will encourage students and their ... ins and outs from many of the industries’ finest ... the New Jersey Institute of Technology, the event will ...
(Date:5/23/2013)... , May 23, 2013  Verenium Corporation (Nasdaq: ... on the development and commercialization of high-performance enzymes, today ... Financial Officer, will present at two upcoming conferences. ... will present at the Second Annual Marcum LLP Microcap ... Hyatt Hotel in New York City.  The presentation is ...
Breaking Biology Technology:The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 3Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 2Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 3Black Data Processing Associates (BDPA) New Jersey Hosts 10th Annual Families in Technology Day June 8, 2013 2Verenium To Present At Two Upcoming Conferences 2Verenium To Present At Two Upcoming Conferences 3
... SAN DIEGO, Feb. 15, 2011 Ceregene, ... and collaborators have published new experimental findings in support ... lead article in the current issue of Movement Disorders ... publication reports the first evidence that gene transfer can ...
... has just launched the first European repository of ... types of reference nanomaterials. This will support safety ... many innovative applications and products. Nanotechnology is one ... a harmonised risk assessment the repository can contribute ...
... RESEARCH TRIANGLE PARK, N.C., Feb. 14, 2011 ... 59th annual Neurological Society of India & Congress ... this past December.  The event was a convergence ... and researchers from across the globe to discuss ...
Cached Biology Technology:Ceregene Reports New Findings Regarding How Parkinson's Brains Respond to Neurotrophic Factors 2Ceregene Reports New Findings Regarding How Parkinson's Brains Respond to Neurotrophic Factors 3Ceregene Reports New Findings Regarding How Parkinson's Brains Respond to Neurotrophic Factors 4Ceregene Reports New Findings Regarding How Parkinson's Brains Respond to Neurotrophic Factors 5Small material, big impact 2Max Neeman International Initiates Advisory Committee to Advance and Improve the Conduct of Complex Neurological Trials in India 2
(Date:5/24/2013)... and other non-coding RNAs are small molecules that ... recent years they have emerged as disease biomarkers. ... origin for cancers of unknown primary origin, determine ... but clinically tractable, diagnostic methods for monitoring miRNA ... In this issue of the Journal of ...
(Date:5/24/2013)... 500 leading water scientists from around the world today ... the short span of one or two generations, the ... be living under the handicap of severe pressure on ... there is no substitute. This handicap will be self-inflicted ... bluntly pointed to chronic underlying problems led by mismanagement ...
(Date:5/23/2013)... National Laboratory honored more than 165 staff for ... at PNNL,s annual Intellectual Property Commercialization Recognition & ... Energy national laboratory named materials scientist Jun Liu ... battery materials that can store large amounts of ... reduce the time it takes to charge cell ...
Breaking Biology News(10 mins):A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists 2A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists 3A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists 4PNNL staff recognized for scientific accomplishments, moving technologies into the marketplace 2
... have developed a commercially viable method for mass producing ... instead of the months required for traditional egg-based vaccines. ... Biodefense Research , The next flu pandemic could happen ... Sciences Corporation (PSC) and a researcher on the study. ...
... to someone talk and also hearing the buzz of the ... conversation down the hallway. To focus on the person speaking ... all incoming sensory information. It has to attend to what ... the Stanford University School of Medicine have taken a big ...
... Allergy and Infectious Diseases (NIAID), part of the ... enrollment into a large international HIV/AIDS trial comparing ... by levels of CD4+ cells has been stopped. ... therapy had twice the risk of disease progression ...
Cached Biology News:New influenza vaccine takes weeks to mass produce 2Stanford study of owls finds link in brain between sight and sound 2Stanford study of owls finds link in brain between sight and sound 3International HIV/AIDS trial finds continuous antiretroviral therapy superior to episodic therapy 2International HIV/AIDS trial finds continuous antiretroviral therapy superior to episodic therapy 3International HIV/AIDS trial finds continuous antiretroviral therapy superior to episodic therapy 4
These stopping screens are for the biolistic PDS-1000 He and Hepta systems. Supplied as 500 screens....
... GEMINI is Tecan's pipetting software for ... GENESIS Freedom and the GENESIS WORKSTATION instruments ... intuitive software enables the user the simple ... of pipetting scripts. With the powerful scripting ...
...
Biotin or fluorescent labels can be attached and the stoichiometry of protein labeling determined....
Biology Products: